Biocon Biologics Marks Major Milestone in Advancing Diabetes Care

Biocon Biologics reported that Biocon Sdn. Bhd., its Malaysian subsidiary, has exceeded the milestone of providing the Malaysian Ministry of Health (MoH) with 100 million recombinant human insulin (rh-insulin) cartridges.Since joining the Malaysian market in 2016, Biocon Biologics has contributed significantly to the revolution in diabetes care, providing more than 345,000 patients with more than 100 million rh-insulin cartridges. A successful strategy for creating a robust biotech ecosystem is demonstrated by Biocon Biologics' public-private cooperation with the Malaysian government, which fosters innovation, nurtures local talent, improves patient outcomes, and advances insulin self-sufficiency in Malaysia.

Susheel Umesh, chief commercial officer, Biocon Biologics, said: “Expanding access to over 345,000 diabetes patients in Malaysia by providing over 100 million cartridges of rh-insulin reinforces our commitment to equitable diabetes care. Every cartridge we produce at our state-of-the-art facility in Johor is a lifeline for someone living with diabetes. Our partnership with the Malaysian Ministry of Health and Duopharma underlines how local manufacturing and global expertise can come together to create scalable, sustainable healthcare solutions for patients.”

Also Read: PharmaTech 2025: India's Premier Pharma & LabTech Event

Leonard Ariff Abdul Shatar, group managing director, Duopharma Biotech Berhad, said: "This significant milestone truly underscores the strength of our enduring, multi-year partnership with Biocon Biologics, an impactful collaboration that aligns with Duopharma Biotech's vision to 'Provide Smarter Solutions for a Healthier Life'. Through our joint efforts, we are committed to elevating diabetes care across Malaysia, ensuring consistent access to affordable, high-quality insulin. We support the Ministry of Health in strengthening public health, and improving the lives of Malaysians living with diabetes.”